Dental Professionals

Ready, Set, Reverse.

It's a whole new direction in distinguishing your practice. And doctors all over the U.S. are introducing their patients to the reality of accelerating the reversal of lingering numbness with OraVerse.

OraVerse is the first and only local anesthesia reversal agent that allows you to bring patients back to normal sensation twice as fast. In clinical trials, the median time to recovery of normal sensation in the upper lip was 50 minutes for OraVerse patients vs. 133 minutes for the control group, and in the lower lip was 70 minutes for OraVerse patients vs. 155 minutes for the control.

In fact, in clinical trials, OraVerse patients were also more quickly able to:

  • Smile
  • Speak
  • Drink normally
  • Minimize drooling

In the trials, the median time to observed recovery of normal function was 60 minutes for patients receiving OraVerse compared to 120 minutes in the mandible and 105 minutes in the maxilla for the control group.

"I don't just get numb, I stay numb for hours. That means half the day is gone before I can feel my lips and tongue again."
        -- Connie L., dental patient, Chicago, Illinois


Market research shows 88% of patients may be interested in receiving a product like OraVerse1. Respondents were aware that a second injection was required and that there may be an extra charge.



OraVerse is indicated for reversal of soft-tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. OraVerse is not recommended for use in children less than 6 years of age or weighing less than 15 kg (33 lbs).

"OraVerse is a great benefit for my patients, and I'm excited to offer it to them."
        -- Dr Lawrence Addleson
           Past President, American Academy of Cosmetic Dentistry


Important Safety Information

In clinical trials, the most common adverse events with OraVerse (phentolamine mesylate) vs. control were post procedural pain (6% vs. 6%), injection site pain (5% vs. 4%), tachycardia (5% vs. 6%), bradycardia (2% vs. 0.3%) and headache (3% vs. 4%). Following parenteral use of phentolamine in non-dental indications, myocardial infarction and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of tachycardia and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease, as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents. See full prescribing information for details.



1. Novalar Research Summary (n=250), Strategic Dental Marketing, Inc., April 2004.